Paul Tudor Jones's SNDX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 69,059 shares of Syndax Pharmaceuticals, Inc. (SNDX) worth $1.61 M, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in SNDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 66,988 shares. Largest reduction occurred in Q1 2024, reducing 68,981 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Syndax Pharmaceuticals (SNDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Syndax Pharmaceuticals (SNDX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +21,638 | Add 45.63% | 69,059 | $23.36 |
| Q4 2025 | -2,763 | Reduce 5.51% | 47,421 | $21.01 |
| Q3 2025 | -2,872 | Reduce 5.41% | 50,184 | $15.39 |
| Q2 2025 | -13,932 | Reduce 20.80% | 53,056 | $9.36 |
| Q1 2025 | +66,988 | New Buy | 66,988 | $12.29 |
| Q4 2024 | -43,070 | Sold Out | 0 | $0.00 |
| Q3 2024 | -4,083 | Reduce 8.66% | 43,070 | $19.25 |
| Q2 2024 | +47,153 | New Buy | 47,153 | $20.53 |
| Q1 2024 | -68,981 | Sold Out | 0 | $0.00 |
| Q4 2023 | +39,042 | Add 130.41% | 68,981 | $21.61 |
| Q3 2023 | +29,939 | New Buy | 29,939 | $14.52 |
| Q1 2023 | -16,581 | Sold Out | 0 | $0.00 |
| Q4 2022 | +16,581 | New Buy | 16,581 | $0.03 |
Paul Tudor Jones's Syndax Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Syndax Pharmaceuticals, Inc. (SNDX) in Q4 2022, acquiring 16,581 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Syndax Pharmaceuticals, Inc. (SNDX) for 13 quarters since Q4 2022.
Paul Tudor Jones's largest addition to Syndax Pharmaceuticals, Inc. (SNDX) was in Q1 2025, adding 66,988 shares worth $822,948.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 69,059 shares of Syndax Pharmaceuticals, Inc. (SNDX), valued at approximately $1.61 M.
As of the Q1 2026 filing, Syndax Pharmaceuticals, Inc. (SNDX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Syndax Pharmaceuticals, Inc. (SNDX) was 69,059 shares, as reported at the end of Q1 2026.